Apimeds Pharmaceuticals US

Company snapshot

Apimeds US is publicly traded on the New York Stock Exchange (Ticker: APUS) and led by a team of experienced biopharma professionals committed to delivering meaningful healthcare advancements. We are actively pursuing licensing and acquisition opportunities to grow our pipeline and expand our impact.

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Apimeds Pharmaceuticals US. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Apimeds Pharmaceuticals US.

1. Jun 8, 2026 Clinical update

   01-13 — Phase 3

2. Jun 8, 2026 Clinical update

   honeybee venom (Apitoxin (Korea) Apitox (USA)) — Phase 2

3. May 23, 2026 Clinical update

   Apitox - pure honeybee toxin — Phase 3

View all clinical trial activity →

• What is Apimeds Pharmaceuticals US?

  Apimeds Pharmaceuticals US is a pharma organization headquartered in Matawan, USA. It trades on NYSE under ticker APUS. Primary therapeutic focus areas include Osteoarthritis of the Knee, Multiple Sclerosis. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 pat

• Is Apimeds Pharmaceuticals US publicly traded?

  Yes. Apimeds Pharmaceuticals US is listed with ticker APUS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Apimeds Pharmaceuticals US develop or market?

  We link 2 drug profile(s) where Apimeds Pharmaceuticals US is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/apimeds-pharmaceuticals-us#company-drugs.

• What are the latest developments for Apimeds Pharmaceuticals US?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Apimeds Pharmaceuticals US focus on?

  Apimeds Pharmaceuticals US focuses on Osteoarthritis of the Knee, Multiple Sclerosis based on our analysis of their pipeline programs and drug development activities.